# Why Do GLP-1 Drugs Cause Nausea? And Why It Does Not Predict Weight Loss Why do GLP-1 drugs cause nausea? They act on the brainstem's area postrema. In STEP 1 to 3, weight loss was similar with or without it | under 1 point ran through it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/why-do-glp1-drugs-cause-nausea Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # Why Do GLP-1 Drugs Cause Nausea? And Why It Does Not Predict Weight Loss The drugs act on a brainstem area that handles both appetite and nausea. In the trials, people with and without stomach side effects lost about the same weight. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Mean weight loss on semaglutide 2.4 mg, STEP 1 to 3 · No GI side effects · 9.6–17.1% · With GI side effects · 11.4–17.7% · Under 1 point of the drug's effect ran through · nausea, vomiting and other GI events. · Darker segment: range across the three trials. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). GLP-1 drugs act on a small brainstem area that, in animal studies, carries both appetite loss and nausea. On semaglutide 2.4 mg, 43.9% of trial participants had nausea, against 16.1% on placebo [\[1\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-1). Feeling sick does not mean the drug is working better. In the same trials, people without stomach side effects lost 9.6% to 17.1% of their weight. People with them lost 11.4% to 17.7%. ## Key takeaways - STEP 1 to 3: nausea in 43.9% on semaglutide 2.4 mg against 16.1% on placebo, mostly mild to moderate and during dose escalation. - Weight loss was similar with or without stomach side effects. Under 1 percentage point of the drug's extra loss ran through them. - SUSTAIN 3, 7 and 10: nausea and vomiting accounted for under 0.1 kg of semaglutide's advantage over other GLP-1 drugs. - SURPASS 1 to 5: tirzepatide weight loss was consistent with or without nausea, vomiting or diarrhea. - In laboratory animals, one brainstem neuron population carried both the weight loss and the aversion. ## Where the nausea comes from Two brainstem areas carry the GLP-1 receptor. One is the nucleus of the solitary tract. The other is the area postrema. A 2026 study silenced each neuron population in turn [\[4\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-4). It also restored the receptor in each on a background where it was otherwise missing. The results split cleanly. Solitary tract neurons restrained normal eating. They did not carry the drug's weight loss. Area postrema neurons played no part in normal eating. They carried both the drug's weight loss and its aversive effect. The authors conclude the two cannot be separated at a circuit level. These are genetic methods in laboratory animals. The abstract does not name the species. How appetite changes at a meal in people is covered in [the food intake guide](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1). ## Why more nausea does not mean more weight loss A shared circuit is not a dose-for-dose link a person can feel. Three sets of human trials tested the link directly. 1. STEP 1 to 3 pooled 2,117 people on semaglutide 2.4 mg and 1,262 on placebo for 68 weeks [\[1\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-1). Weight loss was similar with or without stomach side effects. Semaglutide added 7.6% to 14.4% over placebo. Under 1 percentage point of that ran through those side effects. 2. SUSTAIN 3, 7 and 10 compared semaglutide with other GLP-1 drugs in type 2 diabetes [\[2\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-2). Nausea and vomiting accounted for under 0.1 kg of semaglutide’s extra loss. In SUSTAIN 3 that was 0.09 kg of 3.78 kg. 3. SURPASS 1 to 5 enrolled 6,263 people with type 2 diabetes [\[3\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-3). Tirzepatide weight loss was 6.2 to 14.9 kg with nausea, vomiting or diarrhea. It was 6.2 to 13.3 kg without. Under 6% of tirzepatide’s advantage over comparators ran through stomach side effects. The rule the trials support Nausea is a side effect, not a progress marker. Someone without it is not getting a weaker drug. Someone with a lot of it is not getting a stronger one. ## How long it lasts, and what reduces it In STEP 1 to 3, 99.5% of stomach side events were non-serious. 98.1% were mild to moderate [\[1\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-1). Most were transient and clustered during dose escalation. 4.3% of semaglutide participants stopped the drug because of them. The time course is set out in [how long nausea lasts](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The tools that exist are the dose and the pace of escalation. Both are the prescriber’s decision. The standard semaglutide schedule is in [the starting dose guide](https://thisglp.com/research/semaglutide-starting-dose), and [the titration planner](https://thisglp.com/tools/glp1-titration-planner) maps the steps. ## Whether a drug without nausea is possible One route under study adds a second hormone. In mice, rats and musk shrews, GIP receptor activation blocked vomiting from a GLP-1 drug [\[5\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-5). Reduced food intake and weight loss were kept. That is the preclinical rationale for dual-agonist drugs. It is not a human result. Cross-trial comparisons of nausea rates mix different doses and populations. Head-to-head side-effect data are covered in [the side-effect comparison](https://thisglp.com/research/which-glp1-has-the-worst-side-effects). A product sold as a gentler version needs its own trial data before the claim holds. ## Frequently asked Why do GLP-1 drugs make you nauseous? They act on GLP-1 receptors in the brainstem, including the area postrema, which governs both appetite and nausea. In laboratory animals, the same area postrema neurons carried the weight loss and the aversive effect. Does nausea mean the GLP-1 is working? Not on the trial evidence. In STEP 1 to 3, people without stomach side effects lost 9.6% to 17.1% of their weight and people with them lost 11.4% to 17.7%. Under 1 percentage point of the drug's effect ran through those side effects. If I have no nausea, is my dose too low? Nausea is not a dose gauge. The trials found similar weight loss with or without it, so dose changes are a prescriber decision based on results and tolerability. Does tirzepatide cause less nausea than semaglutide? In animals, GIP receptor activation blocked vomiting from a GLP-1 drug. That does not settle the human question, and nausea rates from separate trials are not directly comparable. ## Sources 1. \[1\] Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity and Metabolism. [PMID 34514682](https://pubmed.ncbi.nlm.nih.gov/34514682/) 2. \[2\] Lingvay I, Hansen T, Macura S, Marre M, Nauck MA, de la Rosa R, et al. (2020). Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events BMJ Open Diabetes Research & Care. [PMID 33115821](https://pubmed.ncbi.nlm.nih.gov/33115821/) 3. \[3\] Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z, et al. (2024). Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials Diabetes, Obesity and Metabolism. [PMID 37853960](https://pubmed.ncbi.nlm.nih.gov/37853960/) 4. \[4\] Yacawych WT, Wang Y, Zhou G, Hassan S, Bodur C, Walters E, et al. (2026). A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists The Journal of Clinical Investigation. [PMID 42742987](https://pubmed.ncbi.nlm.nih.gov/42742987/) 5. \[5\] Borner T, Geisler CE, Fortin SM, Cosgrove R, Alsina-Fernandez J, Dogra M, et al. (2021). GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models Diabetes. [PMID 34380697](https://pubmed.ncbi.nlm.nih.gov/34380697/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness)